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ABSTRACT
Background:  Despite the availability of hundreds of cancer drugs, there is 
insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor 
cell populations of glioblastoma (GBM). 
Results: The PKIS of 357 compounds was initially evaluated in 15 different 
GSC lines which then led to a more focused screening of the 21 most highly active 
compounds in 11 unique GSC lines using HTS screening for cell viability. We further 
validated the HTS result with the second-generation PLK1 inhibitor volasertib as a 
single agent and in combination with ionizing radiation (IR). In vitro studies showed 
that volasertib inhibited cell viability, and high levels of the anti-apoptotic protein Bcl-
xL expression were highly correlated with volasertib resistance. Volasertib sensitized 
GSCs to radiation therapy by enhancing G2/M arrest and by inducing apoptosis. Colony-
formation assay demonstrated that volasertib plus IR synergistically inhibited colony 
formation. In intracranial xenograft mouse models, the combination of volasertib and 
radiation significantly inhibited GSC tumor growth and prolonged median survival 
compared with radiation treatment alone due to inhibition of cell proliferation, 
enhancement of DNA damage, and induction of apoptosis. 
Conclusions: Our results reinforce the potential therapeutic efficacy of volasertib 
in combination with radiation for the treatment of GBM.
Methods: We used high-throughput screening (HTS) to identify drugs, out of 357 
compounds in the published Protein Kinase Inhibitor Set, with the greatest efficacy 
against a panel of glioma stem cells (GSCs), which are representative of the classic 
cancer genome atlas (TCGA) molecular subtypes. 
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INTRODUCTION
Glioblastoma (GBM) is the most common and 
aggressive form of primary brain tumors in adults. 
Current therapy for GBM, using a combination 
of surgery, radiation, and chemotherapy, reduces 
intracranial tumor burden with modest efficacy in 
prolonging survival [1]. Patients with GBM have a mean 
survival of 12 to 14 months from the time of diagnosis, 
with fewer than 5% of patients alive at 3 years [1, 2]. 
Despite the availability of hundreds of cancer drugs, 
there are limited treatment options for patients, and there 
is insufficient information on the efficacy of these drugs 
in the extremely heterogeneous populations of tumor 
cells in GBM [3]. 
GBM displays striking intratumoral heterogeneity 
and a high resistance to radiation and chemotherapy, due 
to the presence of stem-like glioma stem cells (GSCs), 
also called glioma tumor-initiating cells (GSCs). GSCs 
have the ability to undergo self-renewal and initiate 
tumorigenesis, and they are resistant to a wide variety 
of chemotherapeutic agents and possess a remarkable 
ability to recover from cytotoxic therapy [4, 5]. The 
advent of high-throughput screening (HTS) has enabled 
the screening of large, diverse compound libraries 
against a panel of cells to validate targets and identify 
drug candidates for clinical development [6]. Therefore, 
integration of comprehensive HTS of molecularly 
targeted agents with patient-derived GSCs that have been 
extensively profiled by multiple “omics” techniques, 
such as genomics, methylomics and proteomics, provides 
an extraordinary opportunity to develop targeted 
therapies for subsets of patients with GBM [7]. In this 
study, HTS was used to identify drug sensitivities to 357 
compounds in the published Protein Kinase Inhibitor 
Set (PKIS) from GlaxoSmithKline (GSK) using a panel 
of GSCs, which are representative of the classic cancer 
genome atlas (TCGA) molecular subtypes [8] and are 
highly characteristic of human glioma growth patterns 
that contribute to tumor initiation and therapeutic 
resistance.  From the initial 357 compounds, the 21 most 
highly active compounds were more extensively studied. 
This HTS screen identified sensitivity of GSCs to 
inhibitors of polo-like kinase-1 (PLK1), a key regulator 
of mitosis [9]. Given that PLK1 is often overexpressed 
in a broad spectrum of cancers, with highest expression 
levels being correlated with poor prognosis in several 
cancer types [10–13], we further validated the HTS result 
with the second-generation PLK1 inhibitor volasertib 
(BI6727, Boehringer Ingelheim, Germany) as a single 
agent and in combination with ionizing radiation (IR). 
Here, we describe, for the first time, the in vitro and in 
vivo efficacy of volasertib as a single agent and combined 
with radiation in GSCs. 
RESULTS
High-throughput screening of published PKIS 
compounds against GSCs identifies PLK1 as a 
potential therapeutic target for glioblastoma
Two PKIS compound libraries were obtained from 
GlaxoSmithKline, and both compound libraries have 
been tested for kinase activity. The compound structure 
and PKIS data are readily available at ChEMBL [14, 15]. 
The PKIS of 357 compounds was initially evaluated on 
15 different cell lines of GSCs (data not shown) which 
led to a more focused screening of the 21 most highly 
active compounds in 11 unique cell lines of GSCs 
(Supplementary Table 1). We used an IC50 of < 1 µM 
as a cutoff for sensitivity of each compound. We used 
the IC50 cutoff values given that they demonstrated a 
good correlation with area under the curve (AUC)  and 
because IC50 provides a dose reference for further in vitro 
and in vivo experiments (Supplementary Table 2). The 
heatmap depicting the IC50 of 21 compounds against the 11 
GSC lines is shown in Figure 1. Of these 21 compounds, 
we found 8 compounds with potent inhibition of cell 
viability in at least 10 GSC lines; however, some of these 
compounds demonstrated potent activity at nanomolar 
concentrations against a large number of kinases, creating 
challenges in determining mechanism of action. In 
contrast, 10 compounds showed little or no cytotoxicity 
against at least 10 GSC lines. Furthermore, only two 
compounds (GSK978744A and GW301789X) showed 
statistically significant association to TCGA subtypes 
(Supplementary Table 3) but without having any GSCs 
sensitive to these compounds. Interestingly, our HTS data 
showed that 2 GSC lines had IC50 < 1 µM, 8 GSC lines had 
IC50 ranging from 1 to 5 µM, and 1 GSC line had IC50 > 
5 µM for GSK579289A; whereas for GSK317315A, 
1 GSC line had IC50 < 1 µM, 8 GSC lines had IC50 ranging 
from 1 to 5 µM, and 2 GSC lines had IC50 > 5 µM. 
GSK579289A and GSK317315A have been tested 
for kinase inhibitory activity, and both selectively and 
potently inhibit PLK1 (96% inhibition for GSK579289A, 
97% inhibition for GSK317315A) at a low concentration 
(100 nM) [14, 15]. In summary, our HTS assay of PKIS 
compounds against a panel of GSC lines indicated that 
PLK1 is a potential therapeutic target of GBM. 
Inhibition of PLK1 by volasertib results in cell 
cycle arrest and apoptosis in GSCs
PLK1 is often overexpressed in a broad spectrum 
of cancers, including GBM (proteinatlas.org), and high 
PLK1 expression levels correlate with poor prognosis. 
We further verified our HTS results by testing the 
second-generation PLK1 inhibitor volasertib on GSCs. 
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We tested 27 GSC lines to determine their sensitivity 
to volasertib and found that volasertib inhibited cell 
viability with an IC50 ranging from 7.72 nM to 11.4 µM 
(data not shown). Moreover, we correlated proteomic 
RPPA data with volasertib responses of 27 GSC subtypes 
to find predictors of drug sensitivity. Figure 2A shows a 
heatmap from the top 20 significant proteins correlated to 
volasertib sensitivity based on a distinct protein expression 
pattern among sensitive and resistant GSCs. Among these 
proteins, high expression of anti-apoptotic Bcl-2 family 
protein was highly correlated with volasertib resistance 
(P < 0.00033, Figure 2A), suggesting apoptosis contributed 
to the antitumor activity of volasertib. Consistent with 
this finding, treatment with volasertib induced prominent 
poly ADP ribose polymerase cleavage (c-PARP) in a 
dose-dependent and time-dependent manner (Figure 2B), 
suggesting volasterib treatment led to substantial induction 
of apoptosis in GSCs. In addition, Supplementary Figure 1 
shows that Volasertib response has not association with a 
specific TCGA subtype indicating that Volasertib is a good 
candidate for clinical trials independent of tumor subtype.
PLK1 is a critical regulator of cell cycle progression 
[13, 16]. To investigate the effects of volasertib on GSC 
cell cycle distribution, we subjected GSCs to three different 
concentrations (1 nM, 10 nM, and 100 nM) of volasertib for 
different times (16, 24, and 48 hours) and then, measured 
the cell cycle by flow cytometry (Supplementary Figure 2). 
We observed a dose- and time-dependent increase in cells in 
G2/M phase, as well as a sub-G1 accumulation after longer 
exposure to volasertib, indicating that volasertib abrogates 
mitosis followed by induction of apoptosis. These data are 
consistent with our results showing volasertib-mediated 
PARP cleavage and results observed by others in HeLa 
cells, HUVECs and NSCLC [17]. 
PLK1 inhibition by volasertib enhances the 
radiosensitivity of GSCs by modulating cell cycle 
arrest
Given previous findings that radiosensitivity of cells 
is dependent on the phase of the cell cycle [18, 19], with 
cells in S phase being the most radioresistant and cells in 
Figure 1: An HTS assay was used to identity drug sensitivities of 21 compounds in the PKIS (GSK) in a panel of 11 
GSC lines, which were representative of the classic cancer genome atlas (TCGA) molecular subtypes. Heatmap, depicting 
the IC50 of these compounds, identified PLK1 as a therapeutic target of GSC.
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G2/M the most radiosensitive, we examined the combined 
effect of volasertib and radiation on cell cycle arrest. 
Representative and group data of cell cycle distribution, 
shown in Figure 3, demonstrated that inhibition of PLK1 
with volasertib resulted in a dose-dependent G2/M arrest 
and polyploidy production in GSCs. Polyploidy can be 
induced by persistent DNA damage signaling [20, 21], and 
cells unable to undergo mitosis (i.e, mitotic catastrophe) 
can demonstrate polyploidy. Therefore, our data suggest 
that volasertib led to DNA damage and to induction of 
mitotic catastrophe in GSCs. Combining volasertib with 
2 Gy of radiation additively enhanced G2/M arrest and 
polyploidy production. These findings are consistent 
with previous reports showing that PLK1 inhibition with 
GSK461364A in U87 and U251 GBM [22] and with 
BI2536 in medulloblastoma cells [23] induced mitotic 
catastrophe and enhanced radiosensitivity.  
Volasertib synergistically enhances the sensitivity 
to radiation by apoptosis induction, DNA 
damage, and inhibition of colony formation 
To further determine whether PLK inhibition 
enhances the sensitivity of GSCs to radiation, we subjected 
GSCs to different concentrations of volasertib for 24 
hours followed by 2 Gy of radiation. Forty-eight hours 
after radiation, cleaved PARP was significantly greater in 
the combination treatment group than in the volasertib-
treatment alone group (Figure 4A, Supplementary 
Figure 3). Consistent with the induction of apoptosis in the 
combination treatment group, there was a corresponding 
decreased expression of anti-apoptotic protein Bcl-xL and 
an increase expression of pro-apoptotic protein Bad. Similar 
findings were observed with respect to γ-H2AX, an index 
of DNA damage [24], which was significantly higher at 48 
Figure 2: The HTS result was further verified in vitro with the second-generation PLK1 inhibitor volasertib. (A) 
Heatmap from the top ranked 20 proteins associated to Volasertib sensitivity; anti-apoptotic Bcl-2 family proteins were the most significant. 
Correlation of the volasertib IC50 with fold-change (log2) in protein expression in 27 GSC lines demonstrated that high expression levels 
of anti-apoptotic Bcl-2 family proteins were a predictor of resistance to volasertib. (B) Whole-cell protein extracts were analyzed after 
different time points of treatment with different concentrations of volasertib and GSK461364 by Western blot, with the indicated antibodies. 
Representative Western blot data demonstrated that volasertib induced prominent c-PARP in a dose- and time-dependent manner, indicating 
that inhibition of PLK1 resulted in apoptosis in a time- and dose-dependent manner.
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hours following radiation compared with the corresponding 
volasertib-treatment alone group. We further analyzed 
apoptosis by flow cytometry measurement of annexin 
V-propidium iodide staining. As shown in Figure 4B, 
there was no significant difference in apoptosis 48 hours 
after radiation compared with control; however, necrosis 
(as indicated by propidium iodide-positive staining) was 
higher in the radiation-treatment alone group. In contrast, 
apoptosis induction was significantly higher in the cells 
that received 100 nM volasertib plus 2 Gy of radiation than 
in the volasertib-treatment alone group. Taken together, 
these data suggest that the cytotoxic effects of combining 
volasertib and radiation are primarily mediated through 
apoptosis induction.  
We performed the clonogenic (or colony-forming) 
assay, a widely used standard for evaluating radiation 
sensitivity of different cell lines in vitro, to determine 
the effects of volasertib on colony-forming ability and 
compared it with and without radiation. The average 
percentage of colony formation of post-irradiated GSCs 
was significantly lower compared to control, both in 
GSC23 (68.33% ± 0.95% versus 97.20% ± 1.10%, 
P < 0.01) and in GSC272 (96.13% ± 0.57% versus 88.9% 
± 1.10%). Moreover, volasertib treatment at sub-IC50 doses 
(1 nM and 10 nM) resulted in a significant decrease in 
colony formation, which was further reduced by radiation 
treatment (Figure 4C). Together, our data demonstrated 
that the combination of volasertib and radiation 
synergistically inhibited colony formation in vitro.
Combined volasertib and radiation 
synergistically inhibits tumor growth and 
prolongs median survival in vivo
We further examined the combined effect of volasertib 
and radiation on intracranial xenograft models of GSCs. 
Figure 3: G2/M arrest induced by volasertib was additively enhanced by radiation. GSCs were subjected to 2 Gy of ionizing 
radiation after 24 hours of treatment with volasertib, and then cell cycle distribution was analyzed 48 hours after radiation. Representative 
(A) and group (B) data of cell cycle distribution demonstrated that volasertib and radiation had an additive effect on G2/M arrest, in a dose-
dependent manner. Shown are representative data from three individual experiments.
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One week prior to initiating IR, volasertib (10 mg/kg) was 
administrated twice a week until the end of the experiment 
clinically relevant, fractionated IR (2.5 Gy × 4) was applied 
to mice 3 weeks after intracranial implantation of GSCs. 
As expected, mice that received GSC272 (Figure 5A) and 
GSC23 (Figure 5E) showed significantly improved median 
survival upon IR treatment alone compared to untreated 
controls, with median survival prolonged from 62.5 days to 
83.5 days, and 68 days to 81 days respectively. Importantly, 
the combination of volasertib with IR treatment significantly 
improved median survival compared with IR alone in 
mice transplanted with GSC272 (89 days versus 68 days, 
P < 0.001) and with GSC23 (90 days versus 83.5 days, 
P < 0.001). Most importantly, 30% of the mice that received 
combination treatment demonstrated long-term survival 
(sacrificed at 104 days without moribund syndrome), 
whereas 0% of mice survived in the other treatment groups. 
In addition, H&E staining of combination-treated brains 
showed no evidence of significant tumor progression (Figure 
5B), suggesting that some tumors may have prolonged 
benefit from this combination. 
To further examine the effects of single treatment 
and combination treatment on tumor growth in mice, we 
expressed firefly luciferase in GSC272 to monitor tumor 
kinetics using bioluminescent imaging (Figure 5C and 5D). 
IR resulted in a strong decrease in tumor volume; 
however, tumor progression was eventually observed, 
by bioluminescence, at later time points, which suggests 
tumor recurrence. IR in combination with volasertib 
significantly sensitized IR-mediated tumor growth 
inhibition, with a significant delay in tumor volume 
growth compared with IR treatment alone (P < 0.001). 
Combination of volasertib and radiation 
synergistically inhibits tumor cell proliferation, 
induces DNA damage after radiation, and 
induces apoptosis in vivo 
Immunostaining of the proliferation marker 
Ki-67 was performed to identity proliferating cells in the 
xenografts subjected to different treatments. As shown 
in Figure 6A, the Ki-67-positive proliferating tumor cell 
Figure 4: Effects of PLK1 inhibition by volasertib and radiation on apoptosis induction, cell cycle arrest, and clonogenic 
assay for self-renewal of GSCs. (A) Western blotting data showed prominent PARP cleavage in the combination treatment group 
compared with the volasertib treatment alone group. γ-H2AX and cyclin B1 expression levels were higher in the combination treatment 
group than in the volasertib-treatment alone group. (B) Flow cytometric assay of apoptosis by annexin V staining confirmed increased 
apoptosis induction in response to combination treatment than to single treatment. (C) Colony-formation assay demonstrated that volasertib 
combined with radiation had a synergistic effect on inhibiting colony formation in GSCs. Results are expressed as means ± SEM.
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population was significantly inhibited by volasertib, IR, 
and the combination compared with the control group. 
Moreover, significant mitotic cell death, as indicated by 
massive nuclear staining, was observed in the combination 
group. To determine whether volasertib could enhance IR-
mediated DNA damage, γ-H2AX was evaluated 1 week 
following IR. DNA damage was significantly higher in 
the IR group compared with control and volasertib-treated 
groups, and this IR-mediated DNA damage was enhanced 
by treatment with volasertib. However, there was no 
dramatic difference in p-HH3 staining among the groups 
as shown in Figure 6A.
The aforementioned in vitro data suggest that the 
cytotoxic effects of combined volasertib and IR were 
synergistically mediated apoptosis induction; therefore, to 
determine whether similar effects would be observed in 
in vivo models, we assessed apoptosis staining by TUNEL. 
As shown in Figure 6B and 6C, TUNEL staining revealed 
significant apoptosis induction in the combination group 
compared with control and single-treatment groups. This 
Figure 5: The combination of volasertib (10 mg/kg) and radiation (10 Gy) inhibited tumor growth and prolonged 
median survival in an intracranial mouse GSC xenograft model. (A) Kaplan-Meier curve from the GSC272 model showed 
that the radiation group and combination group had significantly prolonged median survival compared with control and volasertib alone 
(P < 0.001 versus control). Notably, the combination treatment group had dramatically extended median survival compared with radiation 
treatment alone (P < 0.001 versus radiation), and the long-term survival of the combination group was 30% compared with 0% in other 
groups. (B) H&E staining of brain after the mice were sacrificed at 104 days after implantation showed no evidence of significant tumor 
progression suggesting that some tumors may have prolonged benefit from this combination. (C) Representative bioluminescent images of 
the GSC272 intracranial mouse xenograft model and the normalized average radiance (photons/s/cm2/sr) with various treatments and time 
points. (D) Radiation reduced tumor growth compared with control, which was further enhanced by combining radiation with volasertib 
(P < 0.001 versus radiation). Results are expressed as means ± SEM. (E) A similar response was seen in the GSC23 intracranial xenograft 
model, in which radiation treatment and combination treatment significantly prolonged median survival.
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pro-apoptotic effect of combined treatment correlated with 
prolonged median survival.
DISCUSSION
Here, we show that PLK1 inhibitor volasertib 
synergistically enhances radiation efficacy in vitro and 
in vivo in GBM.  The following lines of evidence support 
this statement. First, volasertib inhibited the viability of 
GSCs and induced G2/M arrest and apoptosis in a dose- and 
time-dependent manner. Second, GSCs, arrested in M phase 
by volasertib, were more sensitive to IR, as evidence by in 
inducing G2/M arrest, synergism in inducing apoptosis and 
inhibiting colony formation. Previous studies have shown 
that E1A and Ras transformed p53 null and wild type mouse 
embryonic fibroblasts do not undergo significant apoptosis 
after radiation and do not correlate to apoptotic genes Bcl2 
in clonogenic survival assays [25]. However, our results 
shows that in, in vivo xenograft models the combination of 
volasertib and radiation significantly inhibited GSC tumor 
growth and prolonged median survival when compared 
with radiation alone. These differences could be attributed 
to organ specific cellular properties and variation in cell 
growth and culturing conditions. Here we show for the 
first time to our knowledge that high expressions of anti-
apoptotic protein Bcl-xL was a biomarker highly correlated 
with volasertib resistance.
The treatment of GBM remains challenging despite 
meaningful progress, over the past two decades, in the 
molecular treatment of many other cancers, such as lung 
and breast. In recent years, significant progress in our 
understanding of the molecular pathogenesis of GBM 
Figure 6: Combination of volasertib and radiation synergistically inhibits tumor cell proliferation, induces DNA 
damage and apoptosis in vivo. (A) Immunohistochemical analysis of Ki-67, γ-H2AX, and p-HH3 in xenograft tumors that were treated 
with volasertib alone, radiation alone, and volasertib combined with radiation compared with untreated mice. A significant reduction in Ki-
67 staining was observed in the volasertib, radiation, and combination treatment groups compared with control, indicating there were more 
mitotic cell deaths. The DNA damage marker γ-H2AX was enhanced in the radiation treatment group and the combination treatment group 
when the slides were stained the week following radiation. There were no significant p-HH3 changes among groups. (B) A TUNEL assay 
was performed to measure apoptosis in brain sections from GSC xenograft mice, with TUNEL in red and DAPI in blue. Arrows indicate 
examples of TUNEL-positive cells. (C) There were higher numbers of TUNEL-positive cells in the combined volasertib and radiation 
treatment group than in the control, volasertib-treatment alone, or radiation-treatment alone group. (*P < 0.05, **P < 0.01).
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has been made [8, 26–28]. Extensive profiling of the 
GBM genome has identified multiple activated signaling 
pathways that play a central role in cancer cell growth, 
survival, motility, and metabolism, which represent 
potential therapeutic targets [8, 26–28]. However, the 
development of targeted therapy is complicated by the 
complexity and redundancy of these signaling pathways. 
The presence of self-renewing GSCs is thought to 
be responsible for tumor initiation, heterogeneity, and 
resistance to standard therapies. These GSCs closely 
resemble the parent tumor both genotypically and 
phenotypically, thus making the use of GSCs a desirable 
approach for developing more effective therapeutic 
strategies. The Brain Tumor Center at MD Anderson 
Cancer Center has been collecting GSCs from patient 
tumor samples and profiling them by a number of “omics” 
techniques [29, 30]. In this study, we used HTS to identify 
the drug sensitivities of a panel of GSC lines to a panel 
of compounds in PKIS, and we identified sensitivity of 
GSCs to PLK1 inhibitors. Similar results were reported 
by another group, who used high-content imaging-based 
screening assays and who observed that GSCs were 
acutely susceptible to proliferative disruption by PLK1 
inhibitors [31]. 
PLKs are a group of highly conserved serine/
threonine kinases with various key regulatory functions 
during cell cycle progression, and PLK1 is the best 
characterized cancer target in the PLK family [10, 13, 16]. 
PLK1 is overexpressed in several tumor types, including 
breast cancer, non-small cell lung cancer (NSCLC), 
and colorectal cancer, and elevated PLK1 has also been 
correlated with poor prognosis in NSCLC and breast 
cancer patients [13, 32, 33]. Nonetheless, the promising 
effects of PLK1 inhibition in GBM remain poorly 
developed [23, 34, 35]. To further validate the HTS results, 
we used volasertib to investigate the potential therapeutic 
application of PLK1 inhibitors in GBM. Volasertib, a 
second generation dihydropterinone derivative, is a potent 
ATP-competitive selective inhibitor of PLK1, and it also 
inhibits PLK2 and PLK3 [11]. It has demonstrated broad 
antitumor activity with a high volume of distribution, 
indicating good tissue penetration, and a long terminal 
half-life in preclinical studies [36]. Several phase I, II, and 
III clinical trials have evaluated the efficacy of volasertib 
in treating leukemia, lung cancer, and pancreatic cancer 
and have shown encouraging results [11, 12, 37–39]. 
However, few reports have considered the use of volasertib 
in GBM. In the current study, we found that volasertib 
potently inhibited the proliferation of a panel of GSC lines 
with nanomolar IC50. Data from the RPPA studies, verified 
with Western blotting, determined that high expression 
of Bcl-xL was associated with resistance to volasertib 
in the cell lines tested. Consistent with previous studies, 
volasertib promoted mitotic exit delay, which resulted 
in G2/M arrest and subsequent induction of apoptosis 
[22, 23]. Loss of p53 and/or p21Cip1/CDKN1A renders cancer 
cells susceptible to PLK1 inhibition [31, 40]. Further 
studies will be necessary to determine if tumors with p53 
mutations, loss of CDKN1A, or other molecular markers 
are more susceptible to this combination strategy.
Acquired resistance to therapy is a common 
problem in patients with GBM. Of the three main 
therapies for GBM—surgical resection, radiation 
therapy, and chemotherapy—radiation remains the most 
relatively efficacious therapy for primary brain tumors 
[1]. However, many patients have disease refractory to 
radiation therapy, and this radioresistance ultimately 
leads to tumor recurrence. Therefore, there is an urgent 
need to develop strategies to radiosensitize GBM tumor 
cells. Hence, we tested the efficacy of the combination 
of volasertib with radiation in preclinical models, as a 
prerequisite to future clinical studies. The in vitro data in 
this study showed that the combination of volasertib with 
radiation improved radiation efficacy in inhibiting colony 
formation and inducing apoptosis. Here, we show, for the 
first time, that combination treatment significantly delayed 
tumor growth in mice implanted with GSC23 or GSC272, 
and significantly prolonged median survival by inhibiting 
tumor growth and inducing apoptosis. 
One potential limitation of the current study is 
that volasertib treatment alone showed no effects on 
inhibiting in vivo tumor growth or prolonging median 
survival. This may be attributed to poor biodistribution 
of volasertib within the brain, due to a suboptimal dose 
and/or a relatively intact blood-brain barrier. In the 
limited amount of literature reporting on the use of PLK1 
inhibitors, the PLK1 inhibitors with significant antitumor 
effects in GBM have been GSK461364A at 100 mg/kg 
[22] and BI2536 at 50 mg/kg [34]. The dose of volasertib 
that we chose for this study, 10 mg/kg, may not have 
been sufficient as a monotherapy in our complex in vivo 
model. However, radiotherapy can increase blood-brain 
barrier permeability and improve drug delivery to brain 
tumors [41, 42]. Therefore, in our study, radiation therapy 
may have increased the brain biodistribution of 10 mg/kg 
volasertib, leading to synergistic enhancement in radiation 
therapy-mediated tumor growth inhibition and median 
survival prolongation. Moreover, microenvironmental 
factors including hypoxia, molecular heterogeneity, and 
tumor invasion may also limit the in vivo efficacy of 
volasertib alone [2, 43]. Accordingly, we cannot exclude 
the possibility that the beneficial effects of volasertib 
observed in vitro might be less evident in vivo, and further 
optimization of this combined approach is needed to fully 
realize the benefit.
Taken together, the findings of our study both confirm 
and expand on previous in vitro and in vivo studies by 
demonstrating that volasertib inhibits tumor proliferation, 
induces G2/M arrest, and induces apoptosis by sensitizing 
GSCs to radiation to synergistically delay tumor growth 
and prolong median survival. This study has convincingly 
shown that targeting PLK1 with volasertib, in combination 
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with radiation therapy, may be a novel strategy to overcome 
resistance in the treatment of patients with GBM. Additional 
studies will be required to investigate the mechanisms of 
the synergistic effect of this promising combination regimen 
and to further optimize the safety, feasibility, and clinical 
effectiveness of this therapy. 
MATERIALS AND METHODS
GSC isolation and cell culture
GSC lines were isolated from brain tumor specimens 
at The University of Texas MD Anderson Cancer 
Center, Houston, TX. The Institutional Review Board 
of MD Anderson Cancer Center approved acquisition of 
these cell lines from patients, who provided informed 
consent. Glioma stem cell development is funded by 
the MD Anderson Brain Cancer SPORE supported by 
P50CA127001. GSCs were maintained in DMEM/F12 
medium supplemented with B27 supplement (Invitrogen), 
20 ng/ml epidermal growth factor (EGF), and 20 ng/ml 
fibroblast growth factor (FGF) at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air [5, 30]. GSCs were 
tested and authenticated by DNA typing at the MD 
Anderson Cancer Center Cell Line Characterization Core 
and were subsequently verified for our study.
High-throughput screening
GlaxoSmithKline provided the PKIS with 357 
compounds, including the 21 most highly active 
compounds. A panel of GSC cell lines, which have been 
well characterized for their protein and gene expression, 
was screened in 384-well plates at a density of 1000 cells/
well with 16 serially diluted drug concentrations. On the 
same day, 50 nl of each compound was transferred into 
cell wells using the Tecan Evo200 robotic system. Five 
days after drug treatment, cell viability was determined by 
using the CellTiter-Blue cell viability assay and compared 
with values from vehicle control wells to calculate the 
half-maximal inhibitory concentration, IC50. Each cell line 
was screened in duplicate. The quality of the assay was 
estimated by calculating a Z′-factor. Average Z′ value for 
all screens was 0.7 ± 0.5. A separate set of compounds, 
containing doxorubicin and molecularly targeted agents to 
tumor growth factor beta (TGF-β), signal transducer and 
activator of transcription 3 (STAT3), phosphoinositide 
3-kinase (PI3K), and epidermal growth factor receptor 
(EGFR), was used as the positive control plate to compare 
drug efficacy.
Cell cycle and apoptosis analysis by flow 
cytometry
After drug treatment, GSCs were pelleted by 
centrifugation and dissociated with Accutase cell 
detachment solution (Sigma). Cells were collected, 
washed with PBS, and fixed with ice-cold 70% ethanol 
for at least 1 hour. Then, cells were washed twice in PBS, 
treated for 30 minutes at 37°C with PI/RNase Staining 
Buffer (BD Biosciences), and analyzed using a FACScan 
flow cytometer (Becton-Dickinson) to determine subG1 
(apoptosis), G1, S, and G2/M cell cycle distribution. 
Apoptosis was detected using the BD Annexin V FITC 
Assay on the BD FACSVerse System (BD Biosciences).
Clonogenic formation assay
For evaluation of clonogenic formation, post-
treatment GSCs were seeded at 3–5 cells per well in 
triplicate 96-well plates for 3 weeks [29]. Wells with 
neurospheres (>100 micron M) were counted as positive 
and wells without spheres as negative. The percentages of 
positive neurospheres in each plate were compared among 
different treatment groups.
Western blot analysis and reverse-phase protein 
array (RPPA)
Cells were lysed in an ice-cold RIPA lysis buffer 
containing a cocktail of proteinase inhibitors and 
phosphatase inhibitors. The protein concentration in 
the supernatant was determined using the BCA protein 
assay (Pierce Chemical). Samples were subjected to 8% 
to 15% SDS-PAGE, and the separated proteins were 
electrophoretically transferred to PVDF membranes. Blots 
were incubated with the primary antibodies, and then 
incubated with horseradish peroxidase-linked secondary 
anti-rabbit or anti-mouse antibodies (GE). GSC protein 
lysate samples were probed with 279 validated primary 
antibodies for the analysis at the MD Anderson Functional 
Proteomics Reverse Phase Protein Array (RPPA) Core 
facility. (https://www.mdanderson.org/education-and-
research/resources-for-professionals/scientific-resources/
core-facilities-and-services/functional-proteomics-rppa-
core/index.html).
Xenograft models and treatment
GSCs were intracranially implanted, using the guide-
screw system, into 4- to 6-week-old female nude mice 
[44]. One week after guide screw implantation, 500,000 
cells were intracranially injected into each mouse, and the 
mice were randomly distributed to receive different vehicle 
control, volasertib (10 mg/kg), 2.5-Gy IR, or volasertib 
(10 mg/kg) plus 2.5-Gy IR. A minimum of 10 mice was used 
in each treatment group to generate survival curves. For 
in vivo bioluminescent imaging, GSCs were engineered to 
express luciferase by transducing GSCs with pCignal lenti-
CMV-luc viral particles (SABiosciences). Kinetics of tumor 
growth was monitored by IVIS 200 system bioluminescent 
imaging. Two weeks after GSC implantation and one week 
before IR, volasertib (10 mg/kg) was administrated twice a 
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week by oral gavage until the end of the experiment. The 
radiation treatment involved four cycles of 2.5-Gy IR, on 
four consecutive days.  IR was delivered using a 60Co tele-
therapy unit and a custom gig with validated dosimetry. 
Mice with neurological symptoms (i.e., hydrocephalus, 
seizures, inactivity, and/or ataxia) or that were moribund 
were euthanized. Brains were fixed in formalin, stained 
with H&E to confirm the presence of tumor, and subjected 
to immunohistochemical analysis. All animal procedures 
were reviewed and approved by the Institutional Animal 
Care and Use Committee at MD Anderson Cancer Center.
Immunohistochemistry and TUNEL assay
Paraffin sections from xenografts were used 
for immunohistochemical analysis. The slides were 
deparaffinized and subjected to graded rehydration. 
After an antigen retrieval step (citrate buffer, pH 6.0) and 
blocking in 5% serum, the slides were incubated with the 
primary antibodies overnight at 4°C. After washing in PBS 
with Tween 20, primary antibody reactions were detected 
using the Vectastain ABC kit (Vector Laboratories) 
with the appropriate secondary antibody. The apoptosis 
assay in mouse tissues was performed according to the 
manufacturer’s protocol (In Situ Cell Death Detection Kit, 
TMR red; Roche). 
Data analysis
All data are expressed as means ± SEM. One-way 
repeated measures analysis of variance (ANOVA) and two-
way ANOVA followed by post-hoc multiple comparisons 
were used to establish significant differences between 
groups. The Kaplan-Meier curves were compared using 
the log rank test. After log rank comparisons, multiple 
comparisons were performed using the Tukey test. A value 
of P ≤ 0.05 was considered statistically significant.
We used a Wilcoxon Test to calculate p-values to 
compare compounds IC50 with TCGA subtypes, and 
RPPA protein expression between sensitive and resistant 
GSCs. We ranked RPPA proteins according to the 
significance comparing sensitive and resistant GSCs using 
Limma [45] and the R language [46]. Proteins were ranked 
and selected according to p-value.
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